Literature DB >> 33168933

Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?

Sanaz Ghafouri1, John Timmerman2, Sarah Larson3, Monica D Mead4.   

Abstract

Entities:  

Year:  2020        PMID： 33168933      PMCID： PMC8035067          DOI： 10.1038/s41409-020-01099-4

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  1 in total

Review 1.  CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Renier J Brentjens
Journal:  Clin Adv Hematol Oncol       Date:  2016-10
  1 in total
  9 in total

Review 1.  Central Nervous System Lymphoma: Novel Therapies.

Authors:  Shannon P Fortin Ensign; Diamone Gathers; Julia Erin Wiedmeier; Maciej M Mrugala
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

Review 2.  SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma.

Authors:  Jillian Simard; Mark Roschewski
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2022-06-06

3.  Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.

Authors:  Shan Fu; Yongxian Hu; He Huang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2022-04-25

Review 4.  Real-World Experiences of CAR T-Cell Therapy for Large B-Cell Lymphoma: How Similar Are They to the Prospective Studies?

Authors:  Kevin Tang; Loretta J Nastoupil
Journal:  J Immunother Precis Oncol       Date:  2021-08-05

Review 5.  A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.

Authors:  Shebli Atrash; Tamara K Moyo
Journal:  Onco Targets Ther       Date:  2021-03-26       Impact factor: 4.147

6.  CAR T-cell therapy for secondary CNS DLBCL.

Authors:  Gulrayz Ahmed; Mehdi Hamadani; Nirav N Shah
Journal:  Blood Adv       Date:  2021-12-28

Review 7.  CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives.

Authors:  Semira Sheikh; Denis Migliorini; Noémie Lang
Journal:  Biomedicines       Date:  2022-08-12

8.  Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.

Authors:  Huanxin Zhang; Zhiling Yan; Ying Wang; Yuekun Qi; Yongxian Hu; Ping Li; Jiang Cao; Meng Zhang; Xia Xiao; Ming Shi; Jieyun Xia; Sha Ma; Jianlin Qiao; Hujun Li; Bin Pan; Kunming Qi; Hai Cheng; Haiying Sun; Feng Zhu; Wei Sang; Depeng Li; Zhenyu Li; Junnian Zheng; Mingfeng Zhao; Aibin Liang; He Huang; Kailin Xu
Journal:  Front Immunol       Date:  2022-08-19       Impact factor: 8.786

9.  Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.

Authors:  XiaoQin Wu; XinYue Zhang; RenDe Xun; MengSi Liu; Zhen Sun; JianChao Huang
Journal:  Front Immunol       Date:  2021-07-05       Impact factor: 7.561
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.